A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI

Amivantamab and lazertinib

Radiologically confirmed disease progression on previous treatment with osimertinib or lazertinib. Treatment with osimertinib must have been stopped at least 8 days before enrolment.

Presence of a sensitising EGFR-mutation (only patient with exon 19 deletions and/or L858R are eligible), and documentation of T790M status, tested locally by an accredited laboratory.

Patients with symptomatic brain metastases.

Patients with an active or past medical history of leptomeningeal disease